GB0503062D0 - Combination of organic compounds - Google Patents

Combination of organic compounds

Info

Publication number
GB0503062D0
GB0503062D0 GBGB0503062.2A GB0503062A GB0503062D0 GB 0503062 D0 GB0503062 D0 GB 0503062D0 GB 0503062 A GB0503062 A GB 0503062A GB 0503062 D0 GB0503062 D0 GB 0503062D0
Authority
GB
United Kingdom
Prior art keywords
combination
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0503062.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34385460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0503062(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0503062.2A priority Critical patent/GB0503062D0/en
Publication of GB0503062D0 publication Critical patent/GB0503062D0/en
Priority to GT200600049A priority patent/GT200600049A/en
Priority to ARP060100500A priority patent/AR053128A1/en
Priority to TW095104802A priority patent/TW200638928A/en
Priority to PE2006000164A priority patent/PE20061008A1/en
Priority to PCT/EP2006/001285 priority patent/WO2006084757A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0503062.2A 2005-02-14 2005-02-14 Combination of organic compounds Ceased GB0503062D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB0503062.2A GB0503062D0 (en) 2005-02-14 2005-02-14 Combination of organic compounds
GT200600049A GT200600049A (en) 2005-02-14 2006-02-08 VALSARTAN CA / MG SALT COMBINATION WITH AN ANTIDIABETIC AGENT
ARP060100500A AR053128A1 (en) 2005-02-14 2006-02-10 VALSARTAN CA / MG SALT COMBINATION WITH AN ANTIDIABETIC AGENT
TW095104802A TW200638928A (en) 2005-02-14 2006-02-13 Combination of ca/mg salt of valsartan with an antidiabetic agent
PE2006000164A PE20061008A1 (en) 2005-02-14 2006-02-13 COMBINATION OF VALSARTAN Ca / MG SALT WITH AN ANTIDIABETIC AGENT
PCT/EP2006/001285 WO2006084757A2 (en) 2005-02-14 2006-02-13 Combination of ca/mg salt of valsartan with an antidiabetic agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0503062.2A GB0503062D0 (en) 2005-02-14 2005-02-14 Combination of organic compounds

Publications (1)

Publication Number Publication Date
GB0503062D0 true GB0503062D0 (en) 2005-03-23

Family

ID=34385460

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0503062.2A Ceased GB0503062D0 (en) 2005-02-14 2005-02-14 Combination of organic compounds

Country Status (6)

Country Link
AR (1) AR053128A1 (en)
GB (1) GB0503062D0 (en)
GT (1) GT200600049A (en)
PE (1) PE20061008A1 (en)
TW (1) TW200638928A (en)
WO (1) WO2006084757A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008018843A1 (en) * 2006-08-08 2008-02-14 Ulkar Kimya Sanayi Ve Ticaret As Process for producing useful salts form of biphenyl-tetrazole compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001289672B2 (en) * 2000-07-19 2005-12-08 Novartis Ag Valsartan salts
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
EP1734953A4 (en) * 2004-03-02 2008-08-20 Abeille Pharmaceuticals Inc Co-formulations of kits of bioactive agents

Also Published As

Publication number Publication date
WO2006084757A3 (en) 2006-11-23
GT200600049A (en) 2006-09-07
AR053128A1 (en) 2007-04-25
WO2006084757A2 (en) 2006-08-17
TW200638928A (en) 2006-11-16
PE20061008A1 (en) 2006-11-29

Similar Documents

Publication Publication Date Title
IL184426A0 (en) Combination of organic compounds
EP1888534A4 (en) Organic compounds
GB0507575D0 (en) Organic compounds
GB0500435D0 (en) Organic compounds
GB0500785D0 (en) Organic compounds
GB0508319D0 (en) Organic compounds
GB0505969D0 (en) Organic compounds
GB0507696D0 (en) Organic compounds
GB0503646D0 (en) Organic compounds
GB0502358D0 (en) Organic compounds
GB0507577D0 (en) Organic compounds
GB0504850D0 (en) Organic compounds
GB0505219D0 (en) Organic compounds
GB0507298D0 (en) Organic compounds
GB0504194D0 (en) Organic compounds
GB0508992D0 (en) Organic compounds
GB0504544D0 (en) Organic compounds
GB0501237D0 (en) Organic compounds
GB0500784D0 (en) Organic compounds
GB0504203D0 (en) Organic compounds
GB0500683D0 (en) Organic compounds
GB0507695D0 (en) Organic compounds
GB0505541D0 (en) Organic compounds
GB0500020D0 (en) Organic compounds
GB0500682D0 (en) Organic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)